CSCI
Income statement / Annual
Last year (2024), COSCIENS Biopharma Inc.'s total revenue was $9.13 M,
an increase of 27.77% from the previous year.
In 2024, COSCIENS Biopharma Inc.'s net income was -$15.31 M.
See COSCIENS Biopharma Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$9.13 M |
$7.14 M |
$14.57 M |
$13.49 M |
$11.86 M |
$9.86 M |
$8.51 M |
$10.28 M |
$10.17 M |
$7.69 M |
Cost of Revenue |
$4.86 M
|
$4.21 M
|
$6.02 M
|
$5.28 M
|
$5.88 M
|
$5.69 M
|
$4.00 M
|
$4.50 M
|
$3.21 M
|
$2.62 M
|
Gross Profit |
$4.73 M
|
$2.94 M
|
$8.56 M
|
$8.21 M
|
$5.98 M
|
$4.17 M
|
$4.51 M
|
$5.78 M
|
$6.96 M
|
$5.06 M
|
Gross Profit Ratio |
0.52
|
0.41
|
0.59
|
0.61
|
0.5
|
0.42
|
0.53
|
0.56
|
0.68
|
0.66
|
Research and Development Expenses |
$8.30 M
|
$2.04 M
|
$1.37 M
|
$3.04 M
|
$1.48 M
|
$1.83 M
|
$1.96 M
|
$1.28 M
|
$683.82 K
|
$450.54 K
|
General & Administrative Expenses |
$0.00
|
$5.59 M
|
$2.73 M
|
$2.54 M
|
$2.57 M
|
$2.26 M
|
$2.20 M
|
$2.26 M
|
$1.63 M
|
$1.82 M
|
Selling & Marketing Expenses |
$0.00
|
$30.52 K
|
$21.78 K
|
$36.96 K
|
$87.08 K
|
$325.53 K
|
$165.60 K
|
$25.53 K
|
$3.22 K
|
$5.49 K
|
Selling, General & Administrative Expenses |
$10.45 M
|
$5.53 M
|
$2.87 M
|
$2.58 M
|
$2.66 M
|
$2.59 M
|
$2.37 M
|
$2.28 M
|
$1.63 M
|
$1.82 M
|
Other Expenses |
$4.26 M
|
$0.00
|
$0.00
|
$162.26 K
|
$181.37 K
|
$199.56 K
|
$87.17 K
|
$108.60 K
|
$180.69 K
|
$177.70 K
|
Operating Expenses |
$23.01 M
|
$7.57 M
|
$4.24 M
|
$5.78 M
|
$4.32 M
|
$4.62 M
|
$4.41 M
|
$3.67 M
|
$2.49 M
|
$2.45 M
|
Cost And Expenses |
$27.87 M
|
$11.77 M
|
$10.25 M
|
$11.06 M
|
$10.20 M
|
$10.31 M
|
$8.42 M
|
$8.17 M
|
$5.71 M
|
$5.07 M
|
Interest Income |
$441.00 K
|
$59.00 K
|
$145.00 K
|
$0.00
|
$0.00
|
$0.00
|
$263.82 K
|
$77.70 K
|
$148.20 K
|
$131.70 K
|
Interest Expense |
$129.00 K
|
$136.00 K
|
$143.00 K
|
$119.13 K
|
$137.37 K
|
$154.25 K
|
$35.28 K
|
$50.98 K
|
$27.96 K
|
$38.03 K
|
Depreciation & Amortization |
$1.61 M
|
$1.44 M
|
$1.47 M
|
$1.48 M
|
$1.44 M
|
$322.32 K
|
$56.94 K
|
$259.33 K
|
$267.43 K
|
$282.71 K
|
EBITDA |
-$13.49 M |
-$2.84 M |
$6.14 M |
$4.18 M |
$3.04 M |
$686.84 K |
-$216.28 K |
-$29.11 K |
$4.29 M |
$3.08 M |
EBITDA Ratio |
-1.48
|
-0.4
|
0.42
|
0.31
|
0.26
|
0.07
|
-0.03
|
-0
|
0.42
|
0.4
|
Operating Income Ratio |
-2
|
-0.65
|
0.3
|
0.18
|
0.14
|
-0.05
|
0.01
|
0.21
|
0.44
|
0.34
|
Total Other Income/Expenses Net |
$3.06 M
|
$259.00 K
|
$208.00 K
|
$158.65 K
|
-$203.30 K
|
-$420.57 K
|
-$770.40 K
|
-$2.45 M
|
-$473.22 K
|
$146.99 K
|
Income Before Tax |
-$15.23 M
|
-$4.37 M
|
$4.53 M
|
$2.59 M
|
$1.46 M
|
-$869.68 K
|
-$676.36 K
|
-$339.42 K
|
$3.99 M
|
$2.76 M
|
Income Before Tax Ratio |
-1.67
|
-0.61
|
0.31
|
0.19
|
0.12
|
-0.09
|
-0.08
|
-0.03
|
0.39
|
0.36
|
Income Tax Expense |
$84.00 K
|
-$885.00 K
|
$1.08 M
|
-$52.92 K
|
$415.87 K
|
-$2.61 K
|
-$444.70 K
|
$422.63 K
|
$1.30 M
|
-$784.13 K
|
Net Income |
-$15.31 M
|
-$3.49 M
|
$3.45 M
|
$2.64 M
|
$1.46 M
|
-$867.07 K
|
-$231.67 K
|
-$762.05 K
|
$2.69 M
|
$3.55 M
|
Net Income Ratio |
-1.68
|
-0.49
|
0.24
|
0.2
|
0.12
|
-0.09
|
-0.03
|
-0.07
|
0.26
|
0.46
|
EPS |
-5.93 |
-1.89 |
2.51 |
1.69 |
0.85 |
-0.48 |
-0.13 |
-0.43 |
2.13 |
3.38 |
EPS Diluted |
-5.93 |
-1.89 |
2.5 |
1.69 |
0.85 |
-0.48 |
-0.13 |
-0.43 |
2.13 |
3.38 |
Weighted Average Shares Out |
$2.58 M
|
$1.85 M
|
$1.84 M
|
$1.83 M
|
$1.83 M
|
$1.82 M
|
$1.80 M
|
$1.78 M
|
$1.60 M
|
$1.46 M
|
Weighted Average Shares Out Diluted |
$2.58 M
|
$1.85 M
|
$1.85 M
|
$1.85 M
|
$1.84 M
|
$1.82 M
|
$1.80 M
|
$1.78 M
|
$1.68 M
|
$1.54 M
|
Link |
|
|
|
|
|
|
|
|
|
|